Regen BioPharma, Inc. (RGBP)

Regen BioPharma Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Equivalents	0.07	0	0.12	0.05	0.73
Cash & Short-Term Investments	0.07	0	0.12	0.05	0.73
Cash Growth	9614.39%	-99.41%	136.38%	-92.96%	-
Accounts Receivable	0.2	0.09	-	0.25	0.21
Other Receivables	-	-	-	-	0
Receivables	0.2	0.09	-	0.25	0.22
Prepaid Expenses	0	0.05	0.01	0.03	0.05
Total Current Assets	0.27	0.14	0.13	0.34	0.99
Long-Term Investments	-	0.02	0.22	0.22	0.22
Total Assets	0.27	0.16	0.35	0.56	1.21
Accounts Payable	0	0.03	0.03	0.03	0.09
Accrued Expenses	1.84	1.66	1.64	2	2.27
Short-Term Debt	0.19	0.29	0.1	0	1.43
Current Portion of Long-Term Debt	1.01	0.5	0.51	1.27	2.15
Current Unearned Revenue	1.34	1.47	1.61	1.72	1.84
Other Current Liabilities	2.18	1.43	1.42	3.57	6.91
Total Current Liabilities	6.56	5.38	5.31	8.6	14.7
Long-Term Debt	-	-	0.15	-	-
Total Liabilities	6.56	5.38	5.46	8.6	14.7
Common Stock	0	0	0	0.5	0.44
Additional Paid-In Capital	15.63	15.4	14.64	12.32	9.38
Retained Earnings	-21.69	-20.42	-19.75	-20.91	-23.35
Comprehensive Income & Other	-0.22	-0.2	-0	-	-
Total Common Equity	-6.28	-5.22	-5.1	-8.08	-13.53
Shareholders' Equity	-6.28	-5.22	-5.1	-8.04	-13.49
Total Liabilities & Equity	0.27	0.16	0.35	0.56	1.21
Total Debt	1.2	0.79	0.76	1.27	3.58
Net Cash (Debt)	-1.13	-0.79	-0.64	-1.22	-2.86
Net Cash Per Share	-0.05	-0.19	-0.09	-0.19	-0.71
Filing Date Shares Outstanding	108.05	10.52	7.12	6.71	6.09
Total Common Shares Outstanding	39.37	10.52	7.01	6.71	5.8
Working Capital	-6.28	-5.24	-5.18	-8.26	-13.7
Book Value Per Share	-0.16	-0.50	-0.73	-1.21	-2.33
Tangible Book Value	-6.28	-5.22	-5.1	-8.08	-13.53
Tangible Book Value Per Share	-0.16	-0.50	-0.73	-1.21	-2.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.